Lv51
1050 积分 2021-06-22 加入
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/ AKT1/ PTEN Alterations
1个月前
已关闭
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1个月前
已完结
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
1个月前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
1个月前
已完结
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
2个月前
已完结
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
2个月前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China
2个月前
已完结
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer
3个月前
已完结
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
3个月前
已完结
皖公网安备34019202002308
